Deferoxamine therapy of bone aluminum accumulation in renal dialysis patients.
D000293:Adolescent; D000328:Adult; D000535:Aluminum / Q000378:metabolism*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000209:etiology; D001842:Bone and Bones / Q000378:metabolism; D002614:Chelating Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003676:Deferoxamine / Q000627:therapeutic use*; D006801:Humans; D008875:Middle Aged; D010289:Parenteral Nutrition, Total / Q000009:adverse effects; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D006435:Renal Dialysis / Q000009:adverse effects*
D002614:Chelating Agents; D000535:Aluminum; D003676:Deferoxamine